Clinical characteristics and intermediate-term outcomes of young patients with uncomplicated myopericarditis

• Published in: Türk Kardiyoloji Derneği arşivi 2019-10, Vol.47 (7), p.581-586
• Main Authors: Kudret Keskin, Gökhan Çetinkal, Süleyman Sezai Yıldız, Serhat Sığırcı, Güneş Melike Doğan, Kadriye Orta Kılıçkesmez
• Format: Article
• Language: English
• Subjects: anti-inflammatory treatment; colchicine; myopericarditis; recurrence
• ISSN: 1016-5169
• DOI: 10.5543/tkda.2019.63306

Objective: Although the long-term prognosis of myopericarditis is good, recurrence continues to be a problem. In addition, there are concerns regarding the safety of the empirical use of anti-inflammatory drugs. This study was an investigation of the clinical outcomes of young patients with uncomplicated myopericarditis, the majority of whom received both nonsteroidal anti-inflammatory drugs and colchicine. Methods: Patients aged 18 to 40 years who were admitted between May 2015 and May 2018 due to myopericarditis and had normal left ventricular function were included in the study. The primary outcome of the research was analysis of major adverse cardiac events (MACEs): all-cause mortality, myopericarditis recurrence, development of significant arrhythmia, heart failure, and cardiac tamponade. A total of 60 patients were included in the study. The median duration of follow-up was 19 months. Results: A MACE occurred in 11.7% of the patients. None of the patients experienced heart failure, significant arrhythmia, cardiac tamponade, or all-cause mortality. Recurrence of myopericarditis was the only MACE observed. Most patients were treated with both nonsteroidal anti-inflammatory drugs and colchicine (96% and 95% of the patients, respectively). Univariate cox regression analysis indicated that only the maximum in-hospital C-reactive protein (CRP) level was associated with recurrence (hazard ratio: 1.01, 95% confidence interval: 1.01–1.02; p=0.04). Conclusion: The intermediate-term prognosis of myopericarditis patients was excellent in terms of mortality. However, recurrence remains a challenge. The role of CRP, particularly in recurrence, should be explored further.